Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q0AP
|
|||
| Former ID |
DNCL001825
|
|||
| Drug Name |
BMS-582949
|
|||
| Synonyms |
BMS-582949; 623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; PS540446; BMS582949 free base; PS 540446
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atherosclerosis [ICD-11: BD40] | Phase 2 | [1], [2] | |
| Psoriasis vulgaris [ICD-11: EA90] | Phase 2 | [1], [2] | ||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C22H26N6O2
|
|||
| Canonical SMILES |
CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C
|
|||
| InChI |
1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27)
|
|||
| InChIKey |
GDTQLZHHDRRBEB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 623152-17-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein kinase unspecific (PK) | Target Info | Modulator | [3] |
| Stress-activated protein kinase (p38) | Target Info | Inhibitor | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838). | |||
| REF 2 | ClinicalTrials.gov (NCT00605735) PoC in Rheumatoid Arthritis With Methotrexate. U.S. National Institutes of Health. | |||
| REF 3 | Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.